Please login to the form below

Not currently logged in

Cannabis medicines for Alzheimer's disease

Patients suffering from Alzheimer's disease could be treated with cannabis according to new research data

Patients suffering from Alzheimer's disease could be treated with cannabis according to new research data.

During a symposium at the Royal Pharmaceutical Society of Great Britain (RPSGB) on March 10, Professor Raphael Mechoulam of the Hebrew University of Jerusalem presented findings that indicated the potential benefits of cannabis-derived medicines.

Research, which is still in early stages, shows that the chemicals present in cannabis can slow down memory loss, the most prevalent feature of Alzheimer's disease.

Professor Tony Moffat, chairperson of the RPSGB symposium, said: "Although recent press coverage has focused on the abuses associated with the plant, cannabis-derived medications may offer novel opportunities in drug discovery.

"There is currently considerable interest in the medical benefits of cannabis and related compounds for a range of conditions including arthritis, multiple sclerosis and neurological pain."

Alzheimer's disease is the most common form of dementia and affects 417,000 people in the UK and 24.3mn across the world.

The trails conducted so far have only shown the effect of cannabis medicines on mice, but the next step for researchers will be to initiate human patient studies.

10th March 2008


Featured jobs

Subscribe to our email news alerts


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...